Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide

Maurizio Averna; Jeanine Roeters Van Lennep; Rodrigo Alonso

Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide

Maurizio Averna, Jeanine Roeters Van Lennep, Rodrigo Alonso

Risultato della ricerca: Article › peer review

Abstract

Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C). Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor approved as an adjunct to other lipid-lowering therapies (LLTs), with or without lipoprotein apheresis (LA), for the treatment of adult HoFH. Diet with

Lingua originale	English
pagine (da-a)	607-617
Numero di pagine	11
Rivista	JOURNAL OF CLINICAL LIPIDOLOGY
Volume	9
Stato di pubblicazione	Published - 2015

All Science Journal Classification (ASJC) codes

???subjectarea.asjc.2700.2724???
???subjectarea.asjc.2700.2705???
???subjectarea.asjc.2900.2916???
???subjectarea.asjc.2700.2712???

Altri file e collegamenti

Cita questo

@article{4aac43f164b84851a94017f493f61453,

title = "Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide",

abstract = "Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C). Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor approved as an adjunct to other lipid-lowering therapies (LLTs), with or without lipoprotein apheresis (LA), for the treatment of adult HoFH. Diet with",

author = "Maurizio Averna and {Roeters Van Lennep}, Jeanine and Rodrigo Alonso",

year = "2015",

language = "English",

volume = "9",

pages = "607--617",

journal = "JOURNAL OF CLINICAL LIPIDOLOGY",

}

TY - JOUR

T1 - Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide

AU - Averna, Maurizio

AU - Roeters Van Lennep, Jeanine

AU - Alonso, Rodrigo

PY - 2015

Y1 - 2015

N2 - Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C). Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor approved as an adjunct to other lipid-lowering therapies (LLTs), with or without lipoprotein apheresis (LA), for the treatment of adult HoFH. Diet with

AB - Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C). Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor approved as an adjunct to other lipid-lowering therapies (LLTs), with or without lipoprotein apheresis (LA), for the treatment of adult HoFH. Diet with

UR - http://hdl.handle.net/10447/151526

UR - http://www.elsevier.com/wps/find/journaldescription.cws_home/710566/description#description

M3 - Article

VL - 9

SP - 607

EP - 617

JO - JOURNAL OF CLINICAL LIPIDOLOGY

JF - JOURNAL OF CLINICAL LIPIDOLOGY

ER -

Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide

Abstract

All Science Journal Classification (ASJC) codes

Altri file e collegamenti

Fingerprint

Cita questo